• Biosimilars entering the clinic without animal studies: A paradigm shift in the European Union
  • Physicochemical characterization of Remsima®
  • Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response
  • A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies

5 Aug 2014

Biosimilars entering the clinic without animal studies: A paradigm shift in the European Union

Leon AGJM van Aerts, Karen De Smet, Gabriele Reichmann, Jan Willem van der Laan and Christian K Schneider

Physicochemical characterization of Remsima®

Soon Kwan Jung, Kyoung Lee, Jae Won Jeon, Joon Won Lee, Byoung Oh Kwon, YeonJung Kim, Jin Soo Bae, Dong-Il Kim, Soo Young Lee and Shin Jae Chang


5 Aug 2014

Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response

Muhammad Baghdadi, Shintaro Takeuchi, Haruka Wada and Ken-ichiro Seino


1 Jul 2014

 A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies

Jan Stracke, Thomas Emrich, Petra Rueger, Tilman Schlothauer, Lothar Kling, Alexander Knaupp, Hubert Hertenberger, Andreas Wolfert, Christian Spick, Wilma Lau, Georg Drabner, Ulrike Reiff, Hans Koll and Apollon Papadimitriou


Current Issue

mAbs

September/October 2014

Volume 6, Issue 5

View current issue

About the cover image
Physicochemical characterization of the world's first biosimilar monoclonal antibody (mAb), Remsima® , approved by the European Union (EU). Comparison of higher order structures on Fc region by X-ray crystallography. Superimposition of Remsima® (green) and Remicade® (red). For more information, please see Jung et al., this issue.

Recent Articles